Seiji Isonishi

Summary

Affiliation: Jikei University School of Medicine
Country: Japan

Publications

  1. ncbi request reprint Primary chemotherapy-associated effect of second-line chemotherapy on survival of patients with advanced ovarian cancer
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, 4 11 1 Izumi honchou, Komae, Tokyo, 201 8601, Japan
    Int J Clin Oncol 11:236-42. 2006
  2. pmc A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei Daisan Hospital, Tokyo, Japan
    J Gynecol Oncol 24:154-9. 2013
  3. doi request reprint Short-term serum deprivation confers sensitivity to taxanes in platinum-resistant human ovarian cancer cells
    Seiji Isonishi
    Department of Obstetrics Gynecology, Jikei University Daisan Hospital, Izumi honnchou, Komae shi, Tokyo
    Int J Gynecol Cancer 21:1547-54. 2011
  4. doi request reprint Alpha-fetoprotein (AFP)-producing ovarian tumor in an elderly woman
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, Aoto Hospital, Tokyo, Japan
    Int J Clin Oncol 14:70-3. 2009
  5. doi request reprint Small cell carcinoma of the ovary: clinical and biological study
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, Aoto Hospital, 6 41 2 Aoto, Katsushika ku, Tokyo, 125 8506, Japan
    Int J Clin Oncol 13:161-5. 2008
  6. ncbi request reprint Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, 4 11 1 Izumi honnchou, Komae, Tokyo 201 8601, Japan
    Gynecol Oncol 93:647-52. 2004
  7. ncbi request reprint Analysis of prognostic factors for patients with leiomyoma treated with uterine arterial embolization
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, Aoto Hospital, Tokyo, Japan
    Am J Obstet Gynecol 198:270.e1-6. 2008
  8. ncbi request reprint Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, Tokyo 125 8506, Japan
    Oncol Rep 18:195-201. 2007
  9. ncbi request reprint Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells
    Masanori Hirama
    Department of Obstetrics Gynecology and Department of Anatomy II, Jikei University School of Medicine, Minato ku, Tokyo 105, Japan
    Oncol Rep 16:997-1002. 2006
  10. ncbi request reprint Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
    Aikou Okamoto
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, Tokyo, Japan
    Clin Cancer Res 11:6030-9. 2005

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Primary chemotherapy-associated effect of second-line chemotherapy on survival of patients with advanced ovarian cancer
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, 4 11 1 Izumi honchou, Komae, Tokyo, 201 8601, Japan
    Int J Clin Oncol 11:236-42. 2006
    ..The purpose of this study was to evaluate how to make the selection of second-line agents for patients with recurrent ovarian carcinoma initially diagnosed as stage II to IV...
  2. pmc A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei Daisan Hospital, Tokyo, Japan
    J Gynecol Oncol 24:154-9. 2013
    ..To test the concept of taxane sequencing, this feasibility trial evaluated maintenance of docetaxel after paclitaxel and carboplatin combination chemotherapy in patients with stage IC-IV ovarian cancer...
  3. doi request reprint Short-term serum deprivation confers sensitivity to taxanes in platinum-resistant human ovarian cancer cells
    Seiji Isonishi
    Department of Obstetrics Gynecology, Jikei University Daisan Hospital, Izumi honnchou, Komae shi, Tokyo
    Int J Gynecol Cancer 21:1547-54. 2011
    ..Based on the evidences showing that serum deprivation provokes apoptosis in a variety of cells, we have investigated the effect of serum deprivation on drug sensitivity...
  4. doi request reprint Alpha-fetoprotein (AFP)-producing ovarian tumor in an elderly woman
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, Aoto Hospital, Tokyo, Japan
    Int J Clin Oncol 14:70-3. 2009
    ..The patient received secondary cytoreductive surgery of systemic lymphadenectomy, which revealed no evidence of residual tumor...
  5. doi request reprint Small cell carcinoma of the ovary: clinical and biological study
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, Aoto Hospital, 6 41 2 Aoto, Katsushika ku, Tokyo, 125 8506, Japan
    Int J Clin Oncol 13:161-5. 2008
    ..However, an effect of such a regimen was seen in only one patient with early-stage disease, and this questions the validity of chemosensitivity testing...
  6. ncbi request reprint Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, 4 11 1 Izumi honnchou, Komae, Tokyo 201 8601, Japan
    Gynecol Oncol 93:647-52. 2004
    ....
  7. ncbi request reprint Analysis of prognostic factors for patients with leiomyoma treated with uterine arterial embolization
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, Aoto Hospital, Tokyo, Japan
    Am J Obstet Gynecol 198:270.e1-6. 2008
    ..The objective of the study was to describe a clinically useful factors index predicting long-term efficacy of uterine artery embolization (UAE)...
  8. ncbi request reprint Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells
    Seiji Isonishi
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, Tokyo 125 8506, Japan
    Oncol Rep 18:195-201. 2007
    ..These results indicate that orobol and PDGF regulate PX sensitivity by reciprocally altering the proportion of tubulin isotype expression and PX-induced apoptotic signaling...
  9. ncbi request reprint Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells
    Masanori Hirama
    Department of Obstetrics Gynecology and Department of Anatomy II, Jikei University School of Medicine, Minato ku, Tokyo 105, Japan
    Oncol Rep 16:997-1002. 2006
    ..However, the mechanism by which the mitochondrial DNA encoded molecule is involved in cisplatin resistance remains to be determined...
  10. ncbi request reprint Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
    Aikou Okamoto
    Department of Obstetrics and Gynecology, Jikei University School of Medicine, Tokyo, Japan
    Clin Cancer Res 11:6030-9. 2005
    ..We aimed to find key molecules associated with chemoresistance in ovarian cancer using gene expression profiling as a screening tool...
  11. ncbi request reprint Mitochondrial ultrastructure-associated chemotherapy response in ovarian cancer
    Motoaki Saitou
    Department of Obstetrics Gynecology, Jikei University School of Medicine, Tokyo 105, Japan
    Oncol Rep 21:199-204. 2009
    ..In conclusion, this MT scoring system was excellently correlated to response regardless of histopathologic findings and this strongly suggests that the system is deemed to be of great value as biomarker for the chemosensitivity in OC...
  12. doi request reprint Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
    Noriyuki Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Lancet 374:1331-8. 2009
    ..Attempts to improve patient survival by including other drugs have yielded disappointing results. We compared a conventional regimen of paclitaxel and carboplatin with a dose-dense weekly regimen in women with advanced ovarian cancer...
  13. doi request reprint Two cases of epidural anesthesia-associated postoperative decubitus
    Eri Takahashi
    Department of Obstetrics and Gynecology, Jikei University Aoto Hospital, Tokyo, Japan
    J Obstet Gynaecol Res 34:763-6. 2008
    ..Eighteen hours after surgery, the anesthetic effect still continued below the L2 level. We conclude that the extended effect of epidural anesthesia might be one of the mechanisms causing postoperative decubitus...
  14. doi request reprint Possible involvement of glycolipids in anticancer drug resistance of human ovarian serous carcinoma-derived cells
    Kyoko Tanaka
    Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    J Biochem 152:587-94. 2012
    ....
  15. ncbi request reprint Enhancement of sensitivity to cisplatin by orobol is associated with increased mitochondrial cytochrome c release in human ovarian carcinoma cells
    Seiji Isonishi
    Department of Obstetrics Gynecology, Jikei University School of Medicine, 3 25 8 Nishi shinbashi, Minato ku, Tokyo 105, Japan
    Gynecol Oncol 90:413-20. 2003
    ..Based on our previous report showing that orobol, a potent phosphatidylinositol 4-kinase (PI4K) inhibitor, produced cisplatin (DDP) sensitivity, we have determined the mechanism of orobol-sensitization effect...
  16. doi request reprint Characterization of two independent, exposure-time dependent paclitaxel-resistant human ovarian carcinoma cell lines
    Kuninobu Nakajima
    Department of Obstetrics Gynecology Jikei University School of Medicine, Tokyo, Japan
    Hum Cell 23:156-63. 2010
    ..Understanding the characteristics of the differential resistance pattern could be clinically beneficial for the selection of second line chemotherapy for relapsed ovarian cancer...
  17. ncbi request reprint Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer
    Daisuke Aoki
    Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, 160 8582, Japan
    Anticancer Res 29:561-6. 2009
    ..The long-term efficacy and safety of docetaxel/cisplatin as first-line chemotherapy in Japanese patients was evaluated in order to find an optional regimen for ovarian cancer...
  18. doi request reprint Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin
    Yoichi Kobayashi
    Department of Obstetrics and Gynecology, St Marianna University School of Medicine, Japan
    Gynecol Oncol 121:390-4. 2011
    ....
  19. ncbi request reprint [Biomarker in gynecologic malignancies]
    Seiji Isonishi
    Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 3 25 8 Nishishinbashi, Minato ku, Tokyo 105 8461, Japan
    Gan To Kagaku Ryoho 31:1003-7. 2004
    ..For the trials with bevacizumab, anti-VEGF antibody, VEGF and its associated bFGF, CD-31, and thrombospondin-1 (TSP-1), are leading candidates for monitoring markers...
  20. ncbi request reprint [Globalization of anti-cancer therapies]
    Hideyuki Akaza
    Dept of Urology, Institute of Clinical Medicine, University of Tsukuba
    Gan To Kagaku Ryoho 29:205-14. 2002
    ..There have been some recent improvements and further progress is expected so that Japanese doctors can play a full role in the evaluation of new therapies...
  21. ncbi request reprint [Latest information in the diagnoses of ovarian carcinoma]
    Seiji Isonishi
    Dept of Obstetrics and Gynecology, Jikei University School of Medicine
    Gan To Kagaku Ryoho 29:1351-7. 2002
    ..The best selection for adjuvant chemotherapy is still controversial and a large number of studies are now ongoing...
  22. ncbi request reprint [Cancer prevention]
    Hideyuki Akaza
    Dept of Urology, Institute of Clinical Medicine, University of Tsukuba
    Gan To Kagaku Ryoho 32:1499-506. 2005
    ..Overall, cancer prevention is still in evolution. New approaches are needed, and new infrastructure will be needed at a government level to implement this...
  23. ncbi request reprint [Future directions of anticancer drug development in Japan]
    Hideyuki Akaza
    Urology, University of Tsukuba
    Gan To Kagaku Ryoho 35:351-60. 2008
    ..The number of Japanese patients necessary for Phase III studies is individual developmental strategy and needs to be examined by both companies and regulatory agencies...